Evidence map›Paper›PMID 39187313›Full record

ArticleIn vivo (Athens, Greece)

Amine Oxidase, Copper Containing 3 (

Özge Özcan, Özge Akyol, Aytekin Akyol

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Özge ÖzcanDepartment of Stem Cell Sciences, Graduate School of Health Sciences, Hacettepe University, Ankara, Turkey.
Özge AkyolDepartment of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Aytekin AkyolDepartment of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey; aytekina@hacettepe.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimInflammatory bowel diseases and colorectal cancer are a major cause of morbidity and mortality. Amine oxidase, copper-containing 3 (AOC3) is a critical enzyme in the physiological trafficking of leukocytes and the regulation of inflammation. This study aimed to examine the effects of Aoc3 deficiency in mice models of colitis and colorectal tumorigenesis. MATERIALS AND

methodsC57BL/6 and Aoc3 knockout mice were used for Dextran Sodium Sulfate (DSS) induced acute colitis and the Azoxymethane (AOM)/DSS model of inflammation-related colon cancer. We also evaluated the effect of Aoc3 in an Apc mutant mice model of intestinal and colonic tumorigenesis.

resultsWe observed that Aoc3 deficient mice were more prone to colitis induced by DSS in early phases and their survival was shorter. We also showed that Aoc3 deficient mice developed more tumors both in AOM/DSS and Apc mutant mice models. Furthermore, colonic tumors in the AOM/DSS groups in Aoc3 mutant mice were generally invasive type adenocarcinomas.

conclusionAoc3 deficiency promotes colitis and colonic tumorigenesis in mouse models.

Indexed as

Amine Oxidase (Copper-Containing)AzoxymethaneColitisColonic NeoplasmsDextran SulfateDisease Models, AnimalAnimalsCarcinogenesisCell Adhesion MoleculesDisease SusceptibilityMiceMice, Inbred C57BLMice, KnockoutAmine Oxidase (Copper-Containing)AzoxymethaneCell Adhesion MoleculesDextran Sulfatesemicarbazide-sensitive amine oxidase-vascular adhesion protein-1, mouseAoc3colitiscolon cancerInflammatory bowel disease

Identifiers

PMID39187313
PMCPMC11363779

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.